Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Ceribell, Inc. ( (CBLL) ) is now available.
Ceribell, Inc. and Stanford University have amended their exclusive agreement, initially effective from June 15, 2015, to extend the exclusivity of Ceribell’s license for certain portable brain wave activity devices. On June 12, 2025, Ceribell exercised an option to extend this exclusivity by paying a $250,000 fee, which impacts the company’s operations by securing continued access to patented technology.
The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.
Spark’s Take on CBLL Stock
According to Spark, TipRanks’ AI Analyst, CBLL is a Neutral.
Ceribell, Inc. receives a moderate score of 59. The company’s robust revenue growth and strategic advancements are tempered by significant profitability challenges and cash management issues. Technical indicators favor short-term momentum, but the lack of valuation clarity and increased expenses present risks.
To see Spark’s full report on CBLL stock, click here.
More about Ceribell, Inc.
Ceribell, Inc. operates in the medical device industry, focusing on portable devices related to brain wave activity.
Average Trading Volume: 339,825
Technical Sentiment Signal: Strong Sell
Current Market Cap: $643.3M
For detailed information about CBLL stock, go to TipRanks’ Stock Analysis page.